KG006Beyond's analysis on KG0062026-07-31 — Taisho Pharmaceutical secures exclusive Japanese rights to Kaigene’s FcRn inhibitor KG006, unlocking up to $22 million in milestonesRecent news mentioning KG0062026-07-31 — Kaigene Enters into Exclusive Licensing Agreement with Taisho Pharmaceutical for Next-Generation Autoimmune Asset KG006 in JapanAppears alongsideJapanBrowse the full archive →